Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 13/20 | 0.41 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.38 |
| ▸ | CHRNG | P07510 | 1/20 | 0.38 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | CHRND | Q07001 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.38 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12435031 | 1.00 | GRIA2 (0.41) | GRIA2CHRNA1CHRNGCHRNB1CHRNB2 | |
| SCHEMBL2217961 | 1.00 | GRIA2 (0.41) | GRIA2CHRNA1CHRNGCHRNB1CHRNB2 | |
| SCHEMBL2214676 | 1.00 | GRIA2 (0.41) | GRIA2CHRNA1CHRNGCHRNB1CHRNB2 | |
| SCHEMBL2214678 | 1.00 | GRIA2 (0.41) | GRIA2CHRNA1CHRNGCHRNB1CHRNB2 | |
| SCHEMBL2217503 | 1.00 | GRIA2 (0.41) | GRIA2CHRNA1CHRNGCHRNB1CHRNB2 | |
| SCHEMBL2189970 | 0.88 | GRIA2 (0.39) | GRIA2CHRNA1CHRNGCHRNB1CHRNB2 | |
| SCHEMBL2191609 | 0.88 | GRIA2 (0.39) | GRIA2CHRNA1CHRNGCHRNB1CHRNB2 | |
| SCHEMBL2189055 | 0.88 | GRIA2 (0.39) | GRIA2CHRNA1CHRNGCHRNB1CHRNB2 | |
| SCHEMBL2189254 | 0.88 | GRIA2 (0.39) | GRIA2CHRNA1CHRNGCHRNB1CHRNB2 | |
| SCHEMBL2190902 | 0.88 | GRIA2 (0.39) | GRIA2CHRNA1CHRNGCHRNB1CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4584250-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (VG) | 2025-07-16 | — | — | EP | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| US-20110178165-A1 | TETRAHYDROFURANYL SULFONAMIDES AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER INC. | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178165-A1 | TETRAHYDROFURANYL SULFONAMIDES AND PHARMACEUTICAL COMPOSITIONS THEREOF | STS, DHFR, SULT2A1 | GRIA2 1379/4885CHRNA1 4439/4885CHRNG 4777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.